Fortrea Holdings (FTRE) Non-Current Assets (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Non-Current Assets came in at $1.8 billion in Q2 2026, down 4.47% YoY from $1.9 billion in Q2 2025, and down 0.59% on a QoQ basis from $1.8 billion in Q1 2026.
Fortrea Holdings (FTRE) Non-Current Assets (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Non-Current Assets data on file, last reported at $1.8 billion in Q2 2026.
- Quarterly Non-Current Assets fell 4.47% year-over-year to $1.8 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $7.2 billion (down 22.9% YoY) and the FY2025 annual result came in at $1.8 billion, down 30.88% from the prior year.
- Non-Current Assets eased to $1.8 billion in Q2 2026, from $1.8 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $3.1 billion in Q2 2023 to a low of $1.8 billion in Q2 2026.
- A 5-year average of $2.5 billion and a median of $2.7 billion in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets climbed 1.34% — and 2025, when it sank 33.12%.
- Tracing FTRE's Non-Current Assets over 5 years: stood at $3.0 billion in 2022, then grew by 1.34% to $3.1 billion in 2023, then slipped by 14.63% to $2.6 billion in 2024, then sank by 30.88% to $1.8 billion in 2025, then dropped by 1.5% to $1.8 billion in 2026.
- The last three Non-Current Assets figures came in at $1.8 billion (Q2 2026), $1.8 billion (Q1 2026), and $1.8 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Fortrea Holdings | 1.66 Bn | 1.49 Bn | 139.20 Mn | 1.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.79 Bn |
| Mar 31, 2026 | 1.80 Bn |
| Dec 31, 2025 | 1.82 Bn |
| Sep 30, 2025 | 1.82 Bn |
| Jun 30, 2025 | 1.88 Bn |
| Mar 31, 2025 | 2.15 Bn |
| Dec 31, 2024 | 2.63 Bn |
| Sep 30, 2024 | 2.73 Bn |
| Jun 30, 2024 | 2.68 Bn |
| Mar 31, 2024 | 3.04 Bn |
| Dec 31, 2023 | 3.08 Bn |
| Sep 30, 2023 | 3.06 Bn |
| Jun 30, 2023 | 3.12 Bn |
| Dec 31, 2022 | 3.04 Bn |